PMC:7445716 / 43924-44062 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T466","span":{"begin":0,"end":4},"obj":"Disease"},{"id":"T467","span":{"begin":88,"end":90},"obj":"Disease"}],"attributes":[{"id":"A466","pred":"mondo_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/MONDO_0020347"},{"id":"A467","pred":"mondo_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/MONDO_0007886"}],"text":"AIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T239","span":{"begin":5,"end":7},"obj":"Chemical"},{"id":"T240","span":{"begin":52,"end":61},"obj":"Chemical"},{"id":"T241","span":{"begin":63,"end":72},"obj":"Chemical"},{"id":"T242","span":{"begin":95,"end":97},"obj":"Chemical"}],"attributes":[{"id":"A239","pred":"chebi_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A240","pred":"chebi_id","subj":"T240","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A241","pred":"chebi_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A242","pred":"chebi_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/CHEBI_73531"}],"text":"AIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia"}

{"project":"LitCovid-PubTator","denotations":[{"id":"884","span":{"begin":94,"end":105},"obj":"Disease"}],"attributes":[{"id":"A884","pred":"tao:has_database_id","subj":"884","obj":"MESH:D018908"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"AIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia"}

{"project":"LitCovid-sentences","denotations":[{"id":"T226","span":{"begin":0,"end":138},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"AIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T645","span":{"begin":123,"end":138},"obj":"Phenotype"}],"attributes":[{"id":"A645","pred":"hp_id","subj":"T645","obj":"http://purl.obolibrary.org/obo/HP_0001349"}],"text":"AIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T434","span":{"begin":32,"end":50},"obj":"CHEBI:5801;CHEBI:5801;DG_20"},{"id":"T435","span":{"begin":52,"end":61},"obj":"DG_30"},{"id":"T436","span":{"begin":123,"end":129},"obj":"UBERON:0001456"}],"text":"AIDP NA IVIG 400 mg/kg (5 days) Hydroxychloroquine, ritonavir, darunavir Improvement of UL and LL weakness, development of facial diplegia"}